HuGEMM - Immuno-Oncology Model
Evaluate human-specific therapeutics for checkpoint inhibitors, including anti-human PD-1, anti-human PDL-1, and anti-human CTLA-4 antibodies.
This immuno-oncology model was developed by directly replacing the murine PD-1 protein with its human counterpart can be used to evaluate human therapeutics for checkpoint inhibitors including – but not limited to – anti-human PD-1, anti-human PDL-1 and anti-human CTLA-4 antibodies. Source
Get started
To start making requests, simply fill out the registration form below.
Have an account? Sign in.